Head of Regulatory Affairs

Evommune discontinues EVO756 in Atopic Dermatitis after earlier CSU setback. Evommune's EVO756 failed the Phase 2b atopic dermatitis trial, while IL-18BP fusion protein EVO301 advances toward Phase 2b development in 2027. Evommune's oral MRGPRX2 antagonist EVO756 failed to improve atopic dermatitis severity in a Phase 2b trial, marking the second indication discontinued for the drug after its chronic spontaneous urticaria program ended in June 2026. The company will instead advance IL-18BP fusion protein EVO301 in atopic dermatitis while continuing EVO756 development in migraine prophylaxis. EVO756 misses EASI endpoint in Atopic Dermatitis. Evommune's Phase 2b trial of EVO756 in adults with moderate-to-severe atopic dermatitis (AD) failed to meet its primary endpoint, with the oral MRGPRX2 antagonist showing no meaningful benefit across the doses tested. The company will not advance EVO756 in AD following the negative results. The randomized, double-blind, placebo-controlled dose-ranging study enrolled 121 adults and evaluated treatment over 12 weeks, with follow-up through Week 14. EVO756 failed to meet both the primary and secondary efficacy endpoints at all doses studied. The primary endpoint was the percent change from baseline in the Eczema Area and Severity Index (EASI) score at Week 12, a widely used measure of AD severity that assesses the extent and intensity of skin lesions. Targeting MRGPRX2 in chronic inflammation. EVO756 is a potent, selective oral antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor expressed predominantly on mast cells and peripheral sensory neurons. MRGPRX2 contributes to mast-cell activation and inflammatory signaling. By blocking the receptor, EVO756 was being developed as a potential oral approach to modulate pathways implicated in chronic inflammatory disease. Despite the biological rationale, the Phase 2b findings did not translate into clinical efficacy in AD. The company reported that EVO756 was generally well tolerated, with a safety profile consistent with earlier studies. EVO301 takes lead in Atopic Dermatitis pipeline. The setback shifts Evommune's AD development strategy toward EVO301, its long-acting injectable IL-18 binding protein (IL-18BP) fusion protein. EVO301 neutralizes excess IL-18 activity, an inflammatory pathway implicated in chronic immune-mediated diseases. The molecule incorporates native human IL-18BP with high binding affinity and specificity, alongside serum albumin binding to extend its half-life and support sustained IL-18 neutralization. The company plans to move EVO301 into a Phase 2b trial in mid-2027, following positive Phase 2a proof-of-concept results. EVO756 development continues in migraine. Although its AD program will end, Evommune plans to continue developing EVO756 for migraine prophylaxis. The drug's favorable tolerability profile provides support for further clinical evaluation in that setting, although efficacy in migraine remains to be established in future studies. Evommune Chief Medical Officer Eugene Bauer acknowledged the disappointing AD outcome while emphasizing that the safety findings support continued investigation of EVO756 in migraine. Chief Executive Officer Luis Peña said the company remains focused on advancing treatments for chronic inflammatory diseases, with EVO301 now positioned as its lead AD program. Second indication discontinued. The AD failure follows Evommune's decision in June 2026 to discontinue EVO756 development in chronic spontaneous urticaria. Together, the decisions remove two inflammatory disease indications from the drug's development program and leave migraine prophylaxis as the company's continuing clinical focus for EVO756. The repeated setbacks also increase the importance of EVO301 for Evommune's AD strategy. Its Phase 2b study, planned for mid-2027, will provide the next major clinical test of the company's approach to targeting inflammatory pathways in AD. Next development milestones. The immediate priority is EVO301's transition into Phase 2b development, currently expected in mid-2027. For EVO756, further clinical development will focus on migraine prophylaxis rather than AD. The Phase 2b failure highlights the challenge of translating mechanistic rationale into clinical benefit in atopic dermatitis, while EVO301's upcoming study will provide the next major test of Evommune's inflammatory-pathway strategy. The company said its balance sheet supports operations into 2029, providing financial runway for continued development of its clinical portfolio. Reference. Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis, Evommune, 08 September 2026 About the Writer Saniya Sanjay Katakdhond (Linkedin) is a Doctor of Pharmacy professional with hands-on experience in patient case review, clinical documentation, medical record analysis, and patient care. Her hospital experience has strengthened her understanding of clinical conditions, treatment approaches, and multidisciplinary healthcare practices. With ICH-GCP certification and a research-oriented approach, she brings clinical insight and attention to detail to healthcare content development. As a healthcare writer, Saniya focuses on translating clinical knowledge and patient-care experience into clear, accurate, and evidence-informed medical content.

Evommune announces top-line results from EVO756 Phase 2b trial in moderate-to-severe atopic dermatitis. September 08, 2026 at 17:43 PM EDT i This article is third-party content and does not represent the views of this site. Tamar Securities, LLC make no guarantees regarding its accuracy or completeness. - Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated - EVO301, the Company's IL-18BP fusion protein, advances as lead atopic dermatitis program following positive Phase 2a proof-of-concept data - Evommune to continue Phase 2b development of EVO756 in migraine prophylaxis Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist, EVO756, in adults with moderate-to-severe atopic dermatitis (AD). The Phase 2b trial enrolled 121 adults with moderate-to-severe AD over a 12-week treatment period, with follow-up through Week 14, and did not meet the primary and secondary endpoints in any of the doses studied. Based on these results, the Company does not plan to advance EVO756 in AD. "We are disappointed that this trial of EVO756 did not meet its primary endpoint, particularly given the need for new treatment options for patients suffering from AD," said Dr. Eugene Bauer, Chief Medical Officer of Evommune. "EVO756 was generally well tolerated with a safety profile consistent with prior studies, supporting its continued evaluation in migraine prophylaxis. We are sincerely grateful to the patients, clinicians and administrators who participated in this trial." "This trial did not deliver the outcome we and the AD community were hoping for," said Luis Peña, President and Chief Executive Officer at Evommune. "We continue to work towards bringing meaningful clinical benefit to AD patients, and importantly, EVO301, our IL-18BP fusion protein, which recently generated positive Phase 2a proof-of-concept data, will enter a Phase 2b trial planned for mid-2027. With a strong balance sheet supporting operations into 2029, we remain focused on advancing a portfolio of programs with the stated goal of broadly addressing chronic inflammatory diseases." About EVO756 EVO756 is a first-in-class, potent and highly selective oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons. Evommune seeks to produce the first MRGPRX2-targeted oral treatment for chronic inflammatory diseases. About EVO301 EVO301 is a long-acting injectable SAFA-IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity. EVO301 facilitates more efficient tissue distribution and improved binding affinity and specificity relative to existing attempts to antagonize or inhibit the IL-18 pathway, including traditional mAbs. In addition, EVO301 incorporates several distinguishing design features, including selective and high binding affinity of native human IL-18BP and binding to serum albumin, smaller molecular weight, extended half-life for the neutralization of IL-18, and lower potential for immunogenicity. Evommune believes the distinct mechanism and modality of EVO301 provides multiple, potentially synergistic avenues to bring innovative therapeutics to the large, underserved and rapidly expanding population of patients suffering from chronic inflammatory diseases. About Evommune, Inc. Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company's mission is to improve patients' daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow Tamar Securities, LLC on LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of EVO756 and EVO301; the design, objectives, initiation, timing and progress of the Phase 2b clinical trials evaluating EVO756 in migraine and the Phase 2b trial evaluating EVO301 in AD; anticipated cash runway into 2029; and continued advancement of the Company's portfolio. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company's limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company's ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company's ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K, filed with the SEC on March 5, 2026, as supplemented by the Company's Quarterly Report on Form 10-Q, filed with the SEC on August 6, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Contacts. Report this content If you believe this article contains misleading, harmful, or spam content, please let Tamar Securities, LLC know.

Evommune's EVO756 misses primary end point in Phase 2b CSU trial, development continues in AD and migraine. Evommune's EVO756 failed to meet the primary end point in a phase 2b trial for chronic spontaneous urticaria, prompting the company to discontinue development for the indication while continuing studies in atopic dermatitis. recently reported top-line results from its phase 2b trial evaluating EVO756 in adults with moderate -to severe chronic spontaneous urticaria (CSU), with the investigational oral MRGPRX2 antagonist failing to meet its primary efficacy end point. The company said the findings do not support further development of EVO756 for CSU but will continue advancing the therapy in atopic dermatitis (AD) and migraine.[1] The randomized, double-blind, placebo-controlled, dose-ranging phase 2b study enrolled 160 patients with moderate-to severe antihistamine-refractory CSU across the United States, Europe, Canada, and Japan. Participants were randomized to receive 1 of 3 active dose regimens of EVO756 or placebo. The study did not meet its primary end point of mean change from baseline in Urticaria Activity Score over 7 days (UAS7) at week 12, with none of the active treatment groups demonstrating improvement over placebo.[1] "EVO756 previously delivered positive Phase 2 data in chronic inducible urticaria and showed clear target engagement in the Phase 1 trial, however, the lack of efficacy demonstrated at Week 12 in this Phase 2b trial does not support further development of EVO756 for CSU," Eugene Bauer, MD, chief medical officer of Evommune, said in a statement.[1] "We are evaluating EVO756 in additional indications, and this Phase 2b trial confirmed safe and well tolerated doses that warrant these further studies." The company reported no new safety signals, noting that EVO756 was safe and well tolerated across all active dose groups. Earlier promise in MRGPRX2 inhibition. The findings contrast with earlier clinical data for EVO756 in chronic inducible urticaria (CIndU), where the oral therapy demonstrated promising activity in a proof-of-concept study., approximately 30% of patients achieved a complete response after 4 weeks of treatment, while roughly 70% experienced some degree of clinical improvement, supporting continued evaluation of MRGPRX2 inhibition in mast cell-mediated diseases.[2] In a, Mark Jackson, MD, senior vice president of clinical development at Evommune, said the receptor represents a potential therapeutic target because it is expressed on both mast cells and peripheral sensory neurons. He noted that inhibiting MRGPRX2 could provide a novel oral treatment strategy across multiple inflammatory diseases, including AD, by targeting both inflammation and neuroimmune signaling.[3] Pipeline focus shifts to AD and migraine. "While we are disappointed with the trial results in this indication, we continue to believe that modulation of MRGPRX2 represents a new potential therapeutic option to reduce inflammation and provide rapid relief of symptoms," Luis Peña, president and chief executive officer of Evommune, said in the company's announcement.[1] According to Peña, Evommune remains on track to report top-line phase 2b data evaluating EVO756 in AD during the third quarter of 2026. The company has also initiated patient screening for a separate phase 2b study investigating EVO756 as a migraine prophylaxis, with dosing expected to begin in the near term. Beyond EVO756, Evommune continues to advance EVO301, its long-acting injectable IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity. The company recently reported positive phase 2a proof-of-concept data for EVO301 in AD and plans to initiate a phase 2b clinical trial. Peña also noted that Evommune expects its current cash position to support operations through 2028, positioning the company to continue advancing its inflammatory disease pipeline despite the CSU setback. Although EVO756 will no longer be developed for CSU, Evommune's near-term focus now shifts to the ongoing phase 2b AD program, with top-line results expected in the third quarter of 2026, as well as the newly initiated migraine prophylaxis study. References